ProMIS Neurosciences Files 8-K on Financial Results
Ticker: PMN · Form: 8-K · Filed: Mar 25, 2026 · CIK: 0001374339
| Field | Detail |
|---|---|
| Company | Promis Neurosciences Inc. (PMN) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2026 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-update
TL;DR
**ProMIS Neurosciences just dropped an 8-K on financial results, check it for performance updates!**
AI Summary
ProMIS Neurosciences Inc. filed an 8-K on March 25, 2026, reporting its results of operations and financial condition under Item 2.02. This filing, with accession number 0001104659-26-034162, indicates the company is providing an update on its financial performance. For investors, this matters because it offers a timely look into the company's health and operational efficiency, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with crucial, up-to-date information on ProMIS Neurosciences' financial performance, directly impacting their assessment of the company's value and future prospects.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the actual financial results it contains could present either opportunities or risks, making the overall situation medium risk until the details are reviewed.
Analyst Insight
A smart investor would immediately review the full EX-99.1 exhibit to understand the detailed financial results and operational condition reported by ProMIS Neurosciences Inc. before making any investment decisions.
Key Numbers
- 0001104659-26-034162 — SEC Accession No. (Unique identifier for this specific filing)
- 14 — Documents (Total number of documents included in the filing)
- 37890 — Size (Size of the primary 8-K document in bytes)
Key Players & Entities
- ProMIS Neurosciences Inc. (company) — Filer of the 8-K
- 0001374339 (company) — CIK of ProMIS Neurosciences Inc.
- 2026-03-25 (date) — Filing Date and Period of Report
Forward-Looking Statements
- ProMIS Neurosciences Inc. will likely see increased investor scrutiny following the release of its detailed financial results. (ProMIS Neurosciences Inc.) — high confidence, target: 2026-04-25
FAQ
What specific items were reported in this 8-K filing by ProMIS Neurosciences Inc.?
This 8-K filing reported on Item 2.02: Results of Operations and Financial Condition, and Item 9.01: Financial Statements and Exhibits, as indicated in the 'Items' section of the filing.
When was this 8-K filing submitted and accepted by the SEC?
The 8-K filing was submitted and accepted on March 25, 2026, with an acceptance time of 08:06:09, according to the 'Filing Date' and 'Accepted' fields.
What is the CIK number for ProMIS Neurosciences Inc. as listed in this filing?
The CIK number for ProMIS Neurosciences Inc. is 0001374339, as stated in the 'ProMIS Neurosciences Inc. (Filer)' section.
What type of business does ProMIS Neurosciences Inc. primarily engage in, according to its SIC code?
ProMIS Neurosciences Inc. primarily engages in 'Pharmaceutical Preparations,' indicated by its SIC code 2834, as detailed in the 'ProMIS Neurosciences Inc. (Filer)' section.
How many documents are included in this specific 8-K submission?
There are 14 documents included in this 8-K submission, as specified under the 'Documents' field in the filing details.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2026-03-25 08:06:09
Filing Documents
- pmn-20260325x8k.htm (8-K) — 37KB
- pmn-20260325xex99d1.htm (EX-99.1) — 134KB
- pmn-20260325xex99d1001.jpg (GRAPHIC) — 7KB
- 0001104659-26-034162.txt ( ) — 316KB
- pmn-20260325.xsd (EX-101.SCH) — 3KB
- pmn-20260325_def.xml (EX-101.DEF) — 3KB
- pmn-20260325_lab.xml (EX-101.LAB) — 17KB
- pmn-20260325_pre.xml (EX-101.PRE) — 12KB
- pmn-20260325x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On March 25, 2026, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under "Investors/Financial Results"), reporting its financial condition and financial results as of and for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 25, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: March 25, 2026 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer